Dow Jones
36 117,38 +62,95 (+0,17 %) Nasdaq
14 339,99 +193,28 (+1,37 %) Nikkei 225
32 392,11 -466,20 (-1,42 %) EUR/USD
1,0792 -0,0006 (-0,05 %) HANG SENG
16 352,67 +6,78 (+0,04 %) Bitcoin EUR
40 258,10 -461,01 (-1,13 %)
MRK Jan 2025 80.000 call
| Clôture précédente | 26,05 |
| Ouverture | 25,85 |
| Offre | 25,20 |
| Vente | 26,10 |
| Prix d’exercice | 80,00 |
| Date d’expiration | 2025-01-17 |
| Var. jour | 25,85 - 26,05 |
| Gamme de contrats | S.O. |
| Volume | |
| Position de place | 58 |
ACCESSWIREMRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Priority Medicines (PRIME) scheme designation by the European Medicines Agency (EMA) for the adjuvant
- ACCESSWIRE
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful
